ライフサイエンスコーパス: proton pump

1 a highly abundant, pentameric, light-driven proton pump.

2 ein on earth and functions as a light-driven proton pump.

3 r-type ATPase (V-ATPase), a heteromultimeric proton pump.

4 esembles bacteriorhodopsin (BR), an archaeal proton pump.

5 Bacteriorhodopsin (bR) is a light-driven proton pump.

6 r protons, limiting luminal acidification by proton pumps.

7 ay for proton uptake and presumably also for proton pumping.

8 bbs energy, in order to perform work such as proton pumping.

9 lycolysis is essential for V-ATPase-mediated proton pumping.

10 driven rotation by blocking ATPase-dependent proton pumping.

11 ane subunits are found to be responsible for proton pumping.

12 models describing the molecular mechanism of proton pumping.

13 ain their optical properties associated with proton pumping.

14 ia two processes, electrogenic chemistry and proton pumping.

15 ) intermediate that couples this reaction to proton pumping.

16 lar vesicles activates V-ATPase activity and proton pumping.

17 Proton pumping A-type cytochrome c oxidase (CcO) termina

18 ed in the process to thermodynamically drive proton pumping across its membrane domain.

19 Low cytosolic pH required increased proton pumping across the thylakoid membrane and elevate

20 Thus, the interplay between auxin, proton pump activation and expansin action may be more f

21 ver, forced acidification through artificial proton pump activation inhibits root cell elongation.

22 ver, forced acidification through artificial proton pump activation inhibits root cell elongation.

23 Thus, the interplay between auxin, proton pump activation, and expansin action may be more

24 Pilot experiments revealed that the proton pump activator fusicoccin attenuated SWP duration

25 let simultaneously measured the light-driven proton-pumping activities of each bio-pixel.

26 membrane H(+)-ATPase complex, thus reducing proton pump activity to close stomata.

27 atching, accompanied by the onset of gastric proton pump activity.

28 on of endosomes resulting from inhibition of proton pumping activity of vacuolar-type H(+)-ATPase (v-

29 , biosynthesis of secondary metabolites, and proton-pump activity were mainly affected by calcium.

30 embrane protein that synthesizes ATP through proton-pumping activity across the membrane.

31 The proton-pumping activity contributes to the proton electr

32 ATP-hydrolase activity, which is coupled to proton-pumping activity.

33 of the C-terminal domain enabled ATPase and proton-pumping activity.

34 cate a common mechanism of regulation of the proton pump and a potassium channel, two essential eleme

35 Interestingly, the AHA2 proton pump and the FRO2 reductase, both of which work i

36 e membranes assists kinetic coupling between proton pumping and ATP synthesis.

37 aling during cell expansion that coordinates proton pumping and cellulose synthesis.

38 ) exchangers function as electric shunts for proton pumping and in luminal Cl(-) accumulation.

39 of E286 is increased, which slows down both proton pumping and the chemical catalysis.

40 86 through the D-channel, which impairs both proton pumping and the chemical reaction.

41 ments of isolated vesicles containing single proton pumps and compared these results to solutions fro

42 a trimer arrangement reminiscent of BR-like proton pumps and shows features at the extracellular sid

43 of the studied proteins: DTE type (putative proton pump) and NDQ type (putative sodium pump).

44 , gloeobacter rhodopsin (gR), functions as a proton pump, and binds the carotenoid salinixanthin (sal

45 requires extensive adaptations of membranes, proton pumps, and DNA repair mechanisms.

46 The light-activated inhibitory proton pump Archaerhodopsin (Arch) was expressed under c

47 sly available optogenetic tools, such as the proton pump archaerhodopsin-3 (Arch).

48 ction of two different component opsins: the proton pump, Archaerhodopsin and a chloride channel opsi

49 t, following activation of a light-activated proton pump, Archaerhodopsin-3 (Arch), proton transients

50 ing together, we proposed that two tonoplast proton pumps are required for vacuole morphology and PIN

51 Retinal bound light-driven proton pumps are widespread in eukaryotic and prokaryoti

52 gal toxin that activates the plasma membrane proton pump) are impaired, demonstrating that the transp

53 acceptor and donor, a hallmark of rhodopsin proton pumps, are conserved in these cryptophyte protein

54 opy shows a greater accumulation of V-ATPase proton pumps at the apical surface of A-ICs in KO mice c

55 ubic phase SFX structure of the light-driven proton pump bacteriorhodopsin (bR) to 2.3 A resolution a

56 o haloarchaeal rhodopsins, in particular the proton pump bacteriorhodopsin (BR), than to earlier know

57 elease and uptake events in the light-driven proton-pump bacteriorhodopsin and correlate these to oth

58 Shifting the action spectra of these proton pumps beyond 700 nm would generate new prospects

59 ichia coli F1Fo ATP-synthase and the primary proton pump bo3-oxidase, into synthetic lipid vesicles w

60 n can convert the MastR chloride pump into a proton pump but cannot in HRs.

61 he HIGD1 proteins cannot be due to decreased proton pumping by CIV because CIII, operating alone, als

62 f the HIGD1 proteins may be due to decreased proton pumping by complex IV (CIV) or enhanced leak of p

63 ATP regeneration module, the utility of the proton pump can be extended to other applications in the

64 cts on the abundance of sequences related to proton pumps, carbohydrate metabolism, modifications of

65 presented by the interplay between enzymatic proton pumping, carbon influx and the exchange of calcif

66 MBS contains two proton pumps compared to one in MBH and likely conserves

67 Proton-pumping complex I of the mitochondrial respirator

68 e triphosphatases (V-ATPases) are ATP-driven proton pumps comprised of a cytoplasmic V(1) complex for

69 w stochastic elements, such as variations in proton-pump copy number and cycling between on and off s

70 nt role in understanding how these elements (proton pumps, counter-ion fluxes, membrane potential, bu

71 and possibly physically associated with, the proton-pumping cytochrome bcc-aa (3) supercomplex.

72 w-micromolar levels of sulfide inhibited the proton-pumping cytochrome bo oxidase that is regarded as

73 gh the D-channel is kinetically favored over proton pumping due to the loss of a kinetic gate in the

74 internal proton transport events that enable proton pumping during first steps of oxidation of the fu

75 he D-channel is imperative to achieving high proton-pumping efficiency in the WT CcO.

76 d Ca(2+) channels and activates H(+) -ATPase proton pump efflux that dissociates periplasmic AGP-Ca(2

77 Coxs studied to date are redox-driven proton-pumping enzymes belonging to one of three subfami

78 This essential proton pump exists in two activity states: an autoinhibi

79 f the Vacuolar H+ ATPase (V-ATPase), the key proton pump for endo-lysosomal acidification, and two pr

80 oichiometry of complex I (i.e. the number of protons pumped for each two electrons transferred) under

81 opsin (BR) is a heptahelical light-dependent proton pump found in the purple membrane of the archaeon

82 Proteorhodopsin (PR), a light-responsive proton pump from marine bacteria, was used as a model to

83 channel that impair, and sometimes decouple, proton pumping from the chemical catalysis.

84 Besides its canonical proton-pumping function, V-ATPase's membrane sector, Vo,

85 These conditions affect the light-driven proton pumping functional exertion as well.

86 The gastric proton pump H(+),K(+)-ATPase acidifies the gastric lumen

87 In AIG, the gastric proton pump, H(+)/K(+) ATPase, is the major autoantigen

88 Two types of tonoplast proton pumps, H(+) -pyrophosphatase (V-PPase) and the H(

89 Electrogenic proton pumps have been implicated in the generation of s

90 enough to afford electrogenic chemistry and proton pumping, i.e. efficient energy conservation.

91 Complex I functions as a redox-driven proton pump in aerobic respiratory chains.

92 Bacteriorhodopsin (bR), a light-activated proton pump in Archae, has served for many years as a mo

93 lar simulations to study the function of the proton pump in complex I from Thermus thermophilus The s

94 dressed this by expressing a light-activated proton pump in mitochondria to spatiotemporally "turn of

95 vity, suggesting involvement of the V-ATPase proton pump in the phenotype.

96 Complex I functions as a redox-linked proton pump in the respiratory chains of mitochondria an

97 tion step that could thermodynamically drive proton pumping in complex I.

98 We make use of the physical mechanism of proton pumping in the so-called Complex I within mitocho

99 we investigated the function of two types of proton pumps in Arabidopsis embryo development and patte

100 es maintenance of an acidic pH maintained by proton pumps in combination with a counterion transporte

101 with esophageal disease, but the effects of proton pump inhibitor (PPI) drugs are incompletely chara

102 t in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly ac

103 esponse (SVR) included age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV trea

104 Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or responsive, rep

105 RD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary li

106 Proton pump inhibitor (PPI) therapy fails to provide ade

107 mfort persists despite maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately

108 Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fr

109 Demographics, duration of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related

110 present in BE patients are reversible after proton pump inhibitor (PPI) treatment.

111 4.61; 95% CI, 1.42 to 15.0; P = 0.011), and proton pump inhibitor (PPI) use (OR, 3.50; 95% CI, 1.19

112 : Studies have reported associations between proton pump inhibitor (PPI) use and dementia.

113 When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which

114 Between 1997 and 1999, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomi

115 symptoms can be medicated empirically with a proton pump inhibitor (PPI).

116 de concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazol

117 Administration of the proton pump inhibitor omeprazole can reduce both esophag

118 The proton pump inhibitor omeprazole is administered to dogs

119 g methods, enhancing antibiotic and possibly proton pump inhibitor stewardship, and prescribing proph

120 agement considerations (potential indefinite proton pump inhibitor therapy and/or surveillance endosc

121 rch Datalink was additionally used to assess proton pump inhibitor therapy for at least 6 months (med

122 -based triple and high-dose dual amoxicillin proton pump inhibitor therapy for subsequent treatment a

123 imal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 weeks.

124 urgical reintervention and 1192 (59.5%) used proton pump inhibitor therapy, with risk factors for the

125 GERD therapy are a promising alternative to proton pump inhibitor therapy.

126 et agents, had a medical condition requiring proton pump inhibitor treatment, or had already received

127 tburn (mean score 3.2 vs 1.4, p = 0.001) and proton pump inhibitor use (41.7% vs 17.1%, p = 0.023) we

128 Proton pump inhibitor use increases the risk of developi

129 Modification of proton pump inhibitor use may increase rates of SVR.

130 Manometric changes, pH testing, and proton pump inhibitor use were assessed preoperatively a

131 tinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and

132 ores, quality of life metrics, and change in proton pump inhibitor use) and objective metrics (pH par

133 Lower baseline eGFR, proton pump inhibitor use, and combination immune checkp

134 included Model for End-Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c-s

135 g/dL), absence of cirrhosis, and absence of proton pump inhibitor use.

136 duction, or pharmacologically treated with a proton pump inhibitor, the ability of pGP3-deficient C.

137 cy as the positive control of free drug plus proton pump inhibitor, the micromotors can function with

138 py and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4) patients receiving follow-

139 cessful endoscopic therapy receive high-dose proton-pump inhibitor (PPI) therapy (intravenous loading

140 nic hepatitis C virus (HCV) are on prolonged proton-pump inhibitor (PPI) therapy and wish to remain o

141 Heartburn that persists despite proton-pump inhibitor (PPI) treatment is a frequent clin

142 ority of children with EoE not responsive to proton-pump inhibitor (PPI), inflammation is driven by s

143 d received either 10-day sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days a

144 hibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronid

145 Using full-dose proton-pump inhibitor and high-dose Metronidazole in gro

146 Using full-dose proton-pump inhibitor and higher doses of Metronidazole

147 dose Metronidazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastroente

148 Strikingly, the proton-pump inhibitor omeprazole similarly altered the m

149 that were either treated with omeprazole, a proton-pump inhibitor that suppresses acid secretion in

150 ephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval.

151 ndamycin (odds ratio [OR]: 1.23, P = .01) or proton pump inhibitors (OR: 1.20, P < .001) in the 90 da

152 r initial response to any therapy, including proton pump inhibitors (P < .001).

153 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most p

154 Proton pump inhibitors (PPI) are an invaluable therapy o

155 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with a

156 The association between proton pump inhibitors (PPI) use and risk of acute inter

157 (NMA) was conducted to compare the different proton pump inhibitors (PPI) within triple therapy.

158 ion using standard triple therapy (STT) with proton pump inhibitors (PPI), amoxicillin and clarithrom

159 eported on the effects of concomitant use of proton pump inhibitors (PPIs) and dual antiplatelet ther

160 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor a

161 Proton pump inhibitors (PPIs) and histamine-2 receptor a

162 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medicati

163 Proton pump inhibitors (PPIs) are frequently used after

164 Proton pump inhibitors (PPIs) are popular drugs for gast

165 Proton pump inhibitors (PPIs) are used for the long-term

166 Proton pump inhibitors (PPIs) are widely used for the tr

167 Proton pump inhibitors (PPIs) are widely used to treat g

168 reflux esophagitis successfully treated with proton pump inhibitors (PPIs) began 24-hour esophageal p

169 Proton pump inhibitors (PPIs) can contribute to small-bo

170 have hypothesized that the long-term use of proton pump inhibitors (PPIs) can increase the risk of d

171 Proton pump inhibitors (PPIs) have been known to induce

172 Proton pump inhibitors (PPIs) have been recognized as a

173 Safety issues associated with proton pump inhibitors (PPIs) have recently attracted wi

174 Proton pump inhibitors (PPIs) may be a risk factor for h

175 Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for

176 Proton pump inhibitors (PPIs) might reduce the risk of s

177 dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPIs) or first-line therapy rema

178 Proton pump inhibitors (PPIs) or histamine-2 receptor bl

179 Proton pump inhibitors (PPIs) predispose to bacterial ov

180 ncreasing incidence of chronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secret

181 Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebo

182 of patients with GERD who receive label-dose proton pump inhibitors (PPIs) still have symptoms.

183 extraesophageal reflux are often prescribed proton pump inhibitors (PPIs) to reduce gastric acid ass

184 ross-sectional study, 8.5% of patients using proton pump inhibitors (PPIs) were rectal carriers of ex

185 monary disease (COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, nonsteroidal ant

186 e the risks associated with long-term use of proton pump inhibitors (PPIs), focusing on long-term use

187 Proton pump inhibitors (PPIs), frequently prescribed to

188 Proton pump inhibitors (PPIs), which are commonly used a

189 f this association is modulated by intake of proton pump inhibitors (PPIs).

190 s with IPF placed on antacid therapy such as proton pump inhibitors (PPIs).

191 and persistent GERD symptoms despite use of proton pump inhibitors (PPIs).

192 2.6, 95% confidence interval [CI] 1.5-4.7), proton pump inhibitors (PPIs; OR 2.1, 95% CI 1.3-3.4), a

193 nocarcinoma coincided with popularization of proton pump inhibitors and has focused attention on gast

194 phylaxis, review the comparative efficacy of proton pump inhibitors and histamine 2 receptor antagoni

195 r histamine 2 receptor antagonists; however, proton pump inhibitors appear to be the dominant drug cl

196 50% treatment-experienced, and 30% receiving proton pump inhibitors at start of treatment.

197 ibitor, the micromotors can function without proton pump inhibitors because of their built-in proton

198 While proton pump inhibitors have been widely used for blockin

199 ating the efficacy and safety of withholding proton pump inhibitors in critically ill patients.

200 here is very low certainty for the effect of proton pump inhibitors in patients with esophageal eosin

201 les of several commercial controlled-release proton pump inhibitors in simulated stomach and intestin

202 per gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumoni

203 ally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonis

204 ux, defined as use of antireflux medication (proton pump inhibitors or histamine2 receptor antagonist

205 ot clearly support lower bleeding rates with proton pump inhibitors over histamine 2 receptor antagon

206 Here, we show that proton pump inhibitors promote progression of alcoholic

207 Further data integration links proton pump inhibitors to circulating metabolites, liver

208 meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no stat

209 tegy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers

210 Exposure to proton pump inhibitors was found in 53% of cases (47% in

211 Proton pump inhibitors were stopped at least 7 days befo

212 tigation include substituting vonoprazan for proton pump inhibitors, adding probiotics, and vaccine d

213 , change in body mass index, smoking, use of proton pump inhibitors, and anti-diabetic medications, a

214 Lifestyle modifications, proton pump inhibitors, and laparoscopic fundoplication

215 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, and Nissen fundoplication.

216 By contrast, patient age, the use of proton pump inhibitors, and the use of primary prophylax

217 f lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based

218 Therapies include proton pump inhibitors, elimination diets, and topical c

219 apies with evidence of effectiveness include proton pump inhibitors, histamine-2 receptor antagonists

220 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, open fundoplication, and laparos

221 Proton pump inhibitors, PPIs, are widely prescribed and

222 Two proton pump inhibitors, tenatoprazole and esomeprazole,

223 Among patients who used proton pump inhibitors, there was no significant associa

224 Proton pump inhibitors, thyroid hormones, and dihydropyr

225 onomic problem, due to the widespread use of proton pump inhibitors.

226 opy and esophageal pH monitoring, and use of proton pump inhibitors.

227 Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointest

228 f Gastrointestinal Events Trial) showed that proton-pump inhibitors (PPIs) safely reduced rates of ga

229 No proton-pump inhibitors were administered during follow-u

230 antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors, nitroglycerin, diazepam, metoclo

231 Proton-pump inhibitors, PPIs, are considered effective t

232 and reminders to reduce inappropriate use of proton-pump inhibitors.

233 hese patients were successfully treated with proton-pump inhibitors.

234 lar-type ATPases (V-ATPases) are ATP-powered proton pumps involved in processes such as endocytosis,

235 A mechanism for the proton pumping, involving a specific and crucial role fo

236 ur results elucidate the mechanisms by which proton pumping is impaired, thus revealing key kinetic g

237 onstrate that a mutant lacking both of these proton pumps is conditionally viable and retains signifi

238 idoreductase), a membrane-bound redox-driven proton pump, is one of the largest and most complicated

239 ons to bacteriorhodopsin and accelerated the proton pumping kinetics.

240 step plays a central role in activating the proton pumping machinery.

241 complex I has provided new insights into the proton-pumping machinery and a foundation for understand

242 re subunit may be combined with quantitative proton-pumping measurements for mechanistic studies.

243 To better understand the proton-pumping mechanism of the wild-type (WT) CcO, much

244 Mitochondrial proton-pumping NADH:ubiquinone oxidoreductase (respirato

245 the D-channel, and not the H-channel, is the proton pump of the yeast mitochondrial enzyme, supportin

246 roton gradient, ultimately maintained by the proton pumps of the respiratory chain, and Ca(2+) bindin

247 H(+)-ATPase-mediated proton pumping orchestrates cellular homeostasis and is

248 Cytochrome bo3 is a respiratory proton-pumping oxygen reductase that is a member of the

249 olecule level the activity of the prototypic proton-pumping P-type ATPase Arabidopsis thaliana isofor

250 old compared with CEF pathways involving non-proton-pumping plastoquinone reductases.

251 glucose is limiting, however, an ATP-driven proton pump (Pma1) is inactivated, leading to a marked d

252 ptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels.

253 near polar or ionic regions in transmembrane proton pump proteins or hydrogen fuel cell materials.

254 to orient the insertion of the light-driven proton pump proteorhodopsin (PR) into liposomes.

255 ein to function as both a redox enzyme and a proton pump, proton transfer into the protein toward the

256 protein to function as both redox enzyme and proton pump, proton transfer out of either of the channe

257 We conclude that the Proton-Pumping Pyrophosphatase AVP1 localized at the pla

258 Proton-pumping pyrophosphatases (H(+)-PPases) are shown

259 ict similar parameter estimates for the mean proton pumping rate, membrane permeability, etc., but, a

260 equence homology with haloarchaeal rhodopsin proton pumps rather than with previously known channelrh

261 /MM) free energy calculations to explore how proton pumping reactions are triggered within its 200 an

262 llular membrane surface by a light-activated proton pump recruited a slow inward ASIC current, which

263 However, how proton pumps regulate development remains unclear.

264 tively flat membrane plane regions where the proton-pumping respiratory supercomplexes are situated.

265 inct pathways, including the vacuolar ATPase proton pump, Retromer, and Commander complexes.

266 Finally, a new clade of likely proton-pumping rhodopsin with non-canonical amino acids

267 use inhibition of the macrophage H(+)-ATPase proton pump significantly decreased O(2) (*-) detection

268 Some function as outward proton pumps, some as inward chloride pumps, whereas oth

269 The proton-pumping stoichiometry of complex I (i.e. the numb

270 describe a simple method for determining the proton-pumping stoichiometry of complex I in inverted me

271 By virtue of this proton-pumping stoichiometry, we hypothesize that NADPH

272 onsible for the delivery of electrons to the proton pumping subunit.

273 CeMM induced transcription of vacuolar proton pump subunits in hlh-30 mutant worms, and knockdo

274 g an ancestor of many essential redox-driven proton pumps, such as respiratory complex I.

275 on of the vacuolar H(+)-ATPase (V-ATPase), a proton pump that acidifies lysosomes.

276 ATPase; V(1)V(o)-ATPase) is an ATP-dependent proton pump that acidifies subcellular compartments in a

277 r H(+)-ATPase (V-ATPase) is an ATP-dependent proton pump that is essential for cellular homeostasis.

278 complex I is a gigantic (1 MDa) redox-driven proton pump that reduces the ubiquinone pool and generat

279 hodopsin (GR) are retinal-based light-driven proton pumps that absorb visible light (maxima at 520-54

280 Vacuolar ATPases (V-ATPases) are essential proton pumps that acidify the lumen of subcellular organ

281 lar pH is primarily driven by the V-ATPases, proton pumps that use cytoplasmic ATP to load H(+) into

282 ype ATPase and compromised targeting of this proton pump to the plasma membrane upon acid challenge.

283 Mimicking biological proton pumps to achieve stimuli-responsive protonic soli

284 where it is functionally coupled with apical proton pumps to maintain normal acid-base homeostasis.

285 sensitive alternative oxidase (AOX) is a non-proton-pumping ubiquinol oxidase that catalyzes the redu

286 site in the hydrophilic arm to four putative proton-pumping units.

287 ple allow proton transfer to the BNC, but no proton pumping until a proton has reached E286.

288 (CCs) secrete protons into the lumen via the proton pumping V-ATPase located in their apical membrane

289 y epididymal clear cells is achieved via the proton pumping V-ATPase located in their apical membrane

290 Renal intercalated cells (ICs) express the proton pumping vacuolar H(+)-ATPase (V-ATPase) and are e

291 ear-atomic resolution cryoEM structures of a proton-pumping vacuolar ATPase from human cells, illumin

292 ters into synaptic vesicles uses energy from proton-pumping vesicular- or vacuolar-type adenosine tri

293 he hypothesis that mutants lacking tonoplast proton pumps were defective in auxin transport and distr

294 Proton pumps were divided into two subtypes (DTEW and DT

295 ining bacteriorhodopsin (bR), a light-driven proton pump, were arranged on a common hydrogel surface

296 be applicable to the entire family of redox proton pumps, where electron transfer to substrates repl

297 Vps34 lipid kinase complex and the v-ATPase proton pump, whereas Atg genes involved in macroautophag

298 insight enables the utilization of PANI as a proton pump, which is actively tuned through an electroc

299 f the water molecule in the active center of proton pumps, which serves as a bridge for the key proto

300 -2 (KR2), a microbial light-driven sodium or proton pump, with noncovalent mass-spectrometric, electr